title: Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
abstract: OBJECTIVE
  We conducted a phase I study of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for unresectable hepatocellular carcinoma.
  
  
  METHODS
  Sorafenib was administered continuously, whereas cisplatin was administered once every 3 weeks. We estimated the safety and efficacy.
  
  
  RESULTS
  Fifteen patients were enrolled into this study. The dose-limiting toxicities occurred at sorafenib 800 mg and cisplatin 20 mg/m2. The recommended dose was at sorafenib 400 mg and cisplatin 30 mg/m2. The disease control rate was 73.3%.
  
  
  CONCLUSIONS
  This treatment is feasible for unresectable hepatocellular carcinoma. Further evaluation of the regimen in a randomized controlled trial is warranted.
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Morihiko
authors.initials: M
authors.lastname: Ishizaki
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Kaibori
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Matsui
authors.affiliation: b Department of Gastroenterology and Hepatology , Kansai Medical University , Osaka , Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ikeda
authors.affiliation: b Department of Gastroenterology and Hepatology , Kansai Medical University , Osaka , Japan.
authors.forename: Katsunori
authors.initials: K
authors.lastname: Yoshida
authors.affiliation: b Department of Gastroenterology and Hepatology , Kansai Medical University , Osaka , Japan.
authors.forename: Kazuichi
authors.initials: K
authors.lastname: Okazaki
authors.affiliation: c Department of Radiology , Kansai Medical University , Osaka , Japan.
authors.forename: Syuji
authors.initials: S
authors.lastname: Kariya
authors.affiliation: c Department of Radiology , Kansai Medical University , Osaka , Japan.
authors.forename: Noboru
authors.initials: N
authors.lastname: Tanigawa
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Richi
authors.initials: R
authors.lastname: Nakatake
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Matsushima
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Tatsuma
authors.initials: T
authors.lastname: Sakaguchi
authors.affiliation: a Department of Surgery , Kansai Medical University , Osaka , Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Kon
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D002945:Cisplatin
keywords: Chemotherapy; Clinical trials; Hepatoma